Last reviewed · How we verify
MSC-Derived Secretome
MSC-Derived Secretome is a Biologic drug developed by University of the Punjab. It is currently in Phase 1 development. Also known as: Conditioned Medium, MSC Secretome Therapy.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MSC-Derived Secretome |
|---|---|
| Also known as | Conditioned Medium, MSC Secretome Therapy |
| Sponsor | University of the Punjab |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients (PHASE1, PHASE2)
- A Phase II/III Randomized Double-Blind Multicenter Study Comparing UC-MSC-Derived Secretome and Sodium Hyaluronate in Patients With Knee Osteoarthritis (PHASE2, PHASE3)
- Investigating the Safety and Regenerative Potential of MSC-Derived Secretome Combined With PRGF in Knee Osteoarthritis (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSC-Derived Secretome CI brief — competitive landscape report
- MSC-Derived Secretome updates RSS · CI watch RSS
- University of the Punjab portfolio CI
Frequently asked questions about MSC-Derived Secretome
What is MSC-Derived Secretome?
Who makes MSC-Derived Secretome?
Is MSC-Derived Secretome also known as anything else?
What development phase is MSC-Derived Secretome in?
Related
- Manufacturer: University of the Punjab — full pipeline
- Also known as: Conditioned Medium, MSC Secretome Therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing